| 3.38 0.01 (0.3%) | 05-06 14:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.12 |
1-year : | 4.55 |
| Resists | First : | 3.52 |
Second : | 3.9 |
| Pivot price | 3.51 |
|||
| Supports | First : | 2.93 |
Second : | 2.43 |
| MAs | MA(5) : | 3.42 |
MA(20) : | 3.49 |
| MA(100) : | 3.82 |
MA(250) : | 4.58 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 33.2 |
D(3) : | 34 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 7.17 | Low : | 2.79 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RXRX ] has closed above bottom band by 23.1%. Bollinger Bands are 32.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.57 - 3.58 | 3.58 - 3.6 |
| Low: | 3.27 - 3.3 | 3.3 - 3.31 |
| Close: | 3.34 - 3.37 | 3.37 - 3.4 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Wed, 06 May 2026
Earnings call transcript: Recursion Pharmaceuticals Q1 2026 results show EPS beat but revenue miss By Investing.com - Investing.com India
Wed, 06 May 2026
Recursion Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Wed, 06 May 2026
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance Australia
Wed, 06 May 2026
Earnings Flash (RXRX) Recursion Pharmaceuticals Inc Reports Q1 Revenue $6.5M, vs. FactSet Est of $15.8M - marketscreener.com
Wed, 06 May 2026
Recursion Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
Mon, 04 May 2026
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 522 (M) |
| Shares Float | 510 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 64.1 (%) |
| Shares Short | 174,400 (K) |
| Shares Short P.Month | 174,140 (K) |
| EPS | -1.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.14 |
| Profit Margin | 0 % |
| Operating Margin | -328.8 % |
| Return on Assets (ttm) | -27.8 % |
| Return on Equity (ttm) | -59.6 % |
| Qtrly Rev. Growth | 681.7 % |
| Gross Profit (p.s.) | -0.91 |
| Sales Per Share | 0.14 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -372 (M) |
| Levered Free Cash Flow | -209 (M) |
| PE Ratio | -2.34 |
| PEG Ratio | 0 |
| Price to Book value | 1.57 |
| Price to Sales | 23.51 |
| Price to Cash Flow | -4.73 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|